1/15
10:00 am
adct
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
1/13
07:07 pm
adct
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? [Yahoo! Finance]
Low
Report
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? [Yahoo! Finance]
1/13
04:58 pm
adct
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
1/8
04:37 pm
adct
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates [Yahoo! Finance]
Low
Report
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates [Yahoo! Finance]
1/8
04:05 pm
adct
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
Low
Report
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
1/8
10:00 am
adct
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
1/8
07:27 am
adct
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/8
07:15 am
adct
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
1/6
11:56 am
adct
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
1/2
04:18 pm
adct
ADC Therapeutics Announces New Employee Inducement Grant [Yahoo! Finance]
Low
Report
ADC Therapeutics Announces New Employee Inducement Grant [Yahoo! Finance]
1/2
04:05 pm
adct
ADC Therapeutics Announces New Employee Inducement Grant
Low
Report
ADC Therapeutics Announces New Employee Inducement Grant
1/1
10:00 am
adct
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Neutral
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
12/30
12:50 pm
adct
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
12/29
02:06 pm
adct
ADC Therapeutics (ADCT) Upgraded to Buy: Here's Why [Yahoo! Finance]
Low
Report
ADC Therapeutics (ADCT) Upgraded to Buy: Here's Why [Yahoo! Finance]
12/11
10:00 am
adct
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
12/4
07:57 am
adct
ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma [Yahoo! Finance]
Medium
Report
ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma [Yahoo! Finance]
12/3
03:13 pm
adct
ADC Therapeutics (NYSE:ADCT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
High
Report
ADC Therapeutics (NYSE:ADCT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
12/3
11:03 am
adct
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript [Seeking Alpha]
High
Report
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript [Seeking Alpha]
12/3
07:53 am
adct
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma [Yahoo! Finance
High
Report
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma [Yahoo! Finance
12/3
07:30 am
adct
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
High
Report
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
12/2
04:26 pm
adct
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial [Yahoo! Finance]
High
Report
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial [Yahoo! Finance]
12/2
04:05 pm
adct
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
High
Report
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
12/1
04:05 pm
adct
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Medium
Report
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
12/1
11:38 am
adct
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
Low
Report
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
11/12
08:05 am
adct
ADC Therapeutics (NYSE:ADCT) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
ADC Therapeutics (NYSE:ADCT) had its "buy" rating reaffirmed by analysts at Guggenheim.